Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Prospectief, multicenter, niet-interventioneel onderzoek om de effectiviteit van REKOVELLE® voor ovariële stimulatie bij Aziatische vrouwen in de praktijk te onderzoeken (PROFOUND)

29 september 2026 bijgewerkt door: Ferring Pharmaceuticals

Prospectief, niet-interventioneel onderzoek in meerdere landen om REKOVELLE voor ovariële stimulatie te onderzoeken: de effectiviteit, veiligheid en gebruikspatronen voor Aziatische vrouwen in de praktijk

Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Interventie / Behandeling

Studietype

Observationeel

Inschrijving (Werkelijk)

1526

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Hiroshima, Japan, 7300035
        • Ferring Investigational Site
      • Hokkaido, Japan, 0600003
        • Ferring Investigational Site
      • Hyōgo, Japan, 6500021
        • Ferring Investigational Site
      • Osaka, Japan, 5300011
        • Ferring Investigational Site
      • Osaka, Japan, 5500015
        • Ferring Investigational Site
      • Saitama, Japan, 3540035
        • Ferring Investigational Site
    • Chiba
      • Chiba, Chiba, Japan, 2610023
        • Ferring Investigational Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japan, 8120013
        • Ferring Investigational Site
      • Kitakyushu, Fukuoka, Japan, 8070825
        • Ferring Investigational Site
    • Gunma
      • Takasaki, Gunma, Japan, 3700841
        • Ferring Investigational Site
    • Hiroshima
      • Hiroshima, Hiroshima, Japan, 7320822
        • Ferring Investigational Site
    • Japan
      • Bunkyō City, Japan, Japan, 1130033
        • Ferring Investigational Site
    • Tokyo
      • Tokyo, Tokyo, Japan, 1600023
        • Ferring Investigational Site
      • Taichung, Taiwan, 406
        • Ferring Investigational Site
      • Taipei, Taiwan, 100225
        • Ferring Investigational Site
      • Taipei, Taiwan, 110
        • Ferring Investigational Site
    • Tainan
      • Tainan, Tainan, Taiwan, 70403
        • Ferring Investigational Site
      • Tainan, Tainan, Taiwan, 71004
        • Ferring Investigational Site
    • Taoyuan
      • Taoyuan, Taoyuan, Taiwan, 333
        • Ferring Investigational Site
      • Bangkok, Thailand, 10700
        • Ferring Investigational Site
    • Muang
      • Phitsanulok, Muang, Thailand, 65000
        • Naresuan University Hospital
    • Ratchathewi
      • Bangkok, Ratchathewi, Thailand, 10400
        • Ramathibodi Hospital
    • Hanoi
      • Hanoi, Hanoi, Vietnam, 100000
        • Ferring Investigational Site
    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
        • Ferring Investigational Site
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • Ferring Investigational Site
    • Huế
      • Huế, Huế, Vietnam, 49000
        • Ferring Investigational Site
      • Busan, Zuid -Korea, 47245
        • Ferring Investigational Site
      • Seoul, Zuid -Korea, 02586
        • Maria Fertility Hospital
    • Busan
      • Busan, Busan, Zuid -Korea, 49241
        • Ferring Investigational Site
    • Daegu
      • Daegu, Daegu, Zuid -Korea, 41910
        • Ferring Investigational Site
    • Seongnam
      • Seongnam-si, Seongnam, Zuid -Korea, 13496
        • Ferring Investigational Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

20 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

NVT

Geslachten die in aanmerking komen voor studie

Vrouw

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.

Beschrijving

Inclusion Criteria:

  • Females aged 20 years or older at enrollment
  • Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
  • Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
  • Participating in an interventional clinical trial in which any medication treatment is mandated
  • Women with a contraindication for prescription of REKOVELLE treatment
  • Oocyte donors
  • Undergoing ovarian stimulation for fertility preservation

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
REKOVELLE

Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.

Individualised dosing regiment of REKOVELLE in routine clinical practice.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cumulative live birth rate
Tijdsspanne: Up to 12 months

Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

Up to 12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The Luteinising hormone (LH) surge suppression protocol
Tijdsspanne: Up to 22 days

Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol.

Up to 22 days
Daily Dosage
Tijdsspanne: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage.

Up to 22 days
Stimulation Duration
Tijdsspanne: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration.

Up to 22 days
Total Dosage
Tijdsspanne: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage.

Up to 22 days
Trigger Protocol
Tijdsspanne: Up to 22 days

Treatment pattern will be measured by analysing the trigger protocol.

Up to 22 days
Luteal phase support protocol
Tijdsspanne: Up to 22 days

Treatment pattern will be measured by analysing the luteal phase support protocol.

Up to 22 days
Number of oocytes retrieved
Tijdsspanne: Up to 22 days

Number of oocytes retrieved at oocyte retrieval

Up to 22 days
Number of Metaphase II (MII) oocytes
Tijdsspanne: Up to 22 days

Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI))

Up to 22 days
Number of embryos
Tijdsspanne: Day 3 after oocyte retrieval

Number of embryos on Day 3 after oocyte retrieved

Day 3 after oocyte retrieval
Number of Blastocysts
Tijdsspanne: Day 5 after oocyte retrieval

Number of Blastocysts on Day 5 after oocyte retrieved

Day 5 after oocyte retrieval
Number of embryos transferred
Tijdsspanne: Up to 28 days

Embryos transferred in fresh and/or frozen transfer cycles

Up to 28 days
Number of blastocysts transferred
Tijdsspanne: Up to 28 days

Blastocysts transferred in fresh and/or frozen transfer cycles

Up to 28 days
Implantation rate
Tijdsspanne: Up to 28 days

Number of gestational sacs, embryos or blastocysts transferred

Up to 28 days
Positive human chorionic gonadotropin (hCG) rate
Tijdsspanne: 11 to 15 days after transfer

Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer

11 to 15 days after transfer
Clinical Pregnancy rate
Tijdsspanne: 4 to 5 weeks after transfer

Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer)

4 to 5 weeks after transfer
Vital Pregnancy
Tijdsspanne: 4 to 5 weeks after transfer

Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer)

4 to 5 weeks after transfer
Ongoing pregnancy rate
Tijdsspanne: 9 to 11 weeks after transfer

Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer)

9 to 11 weeks after transfer
Time to pregnancy
Tijdsspanne: 4 to 5 weeks after transfer

Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy

4 to 5 weeks after transfer
Live birth rate
Tijdsspanne: More than 20 weeks after transfer

Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

More than 20 weeks after transfer
Multiple pregnancy rate
Tijdsspanne: 4 to 5 weeks after transfer

More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer

4 to 5 weeks after transfer
Spontaneous abortion rate
Tijdsspanne: Up to 10-11 weeks after transfer

Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound

Up to 10-11 weeks after transfer
Ectopic pregnancy rate
Tijdsspanne: Up to 10-11 weeks after transfer

Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.

Up to 10-11 weeks after transfer
Estradiol Hormone levels
Tijdsspanne: Up to 20 days

Estradiol hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Progesterone Hormone levels
Tijdsspanne: Up to 20 days

Progesterone hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Cycle cancellation rate and the reason for cycle cancellation
Tijdsspanne: Up to 28 days

Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason)

Up to 28 days
Transfer cancellation rate and the reason for transfer cancellation
Tijdsspanne: Up to 28 days

Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation).

Up to 28 days
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Tijdsspanne: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Frequency and severity of ADRs and SAEs as defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Tijdsspanne: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.

Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer)

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Tijdsspanne: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Number of subjects with mild / moderate / severe OHSS, defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Global Clinical Compliance, Ferring Pharmaceuticals

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

27 augustus 2024

Primaire voltooiing (Geschat)

1 mei 2027

Studie voltooiing (Geschat)

1 augustus 2027

Studieregistratiedata

Eerst ingediend

6 augustus 2024

Eerst ingediend dat voldeed aan de QC-criteria

16 augustus 2024

Eerst geplaatst (Werkelijk)

20 augustus 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 september 2026

Laatste update ingediend die voldeed aan QC-criteria

29 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 000430

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren